Monday, 14 November 2011 11:06

MPI Research Congratulates Dr. David Serota, Incoming President Of American College Of Toxicology

MPI Research is pleased to announce that David Serota, PhD, DABT, Senior Vice President of Drug Safety Development and Senior Principal Study Director, will serve as the 2012 American College of Toxicology (ACT) President.

Dr. Serota has been a member of ACT since 1981 and served a three-year term on the Membership Committee, a three-year term as Councilor, one year as Vice President, and one year as President-Elect. During his role as Vice President he chaired the Awards Committee, and most recently chaired the Program Committee as President-Elect. Dr. Serota received his undergraduate degree in pharmacy from Auburn University in 1969 and his doctorate in toxicology from the University of Tennessee Medical Center in 1976. After graduation he was an assistant professor in the School of Pharmacy at Washington State University for one year before deciding to enter the world of preclinical toxicology contract research, where he has held numerous scientific and leadership positions over the past 34 years. Before joining MPI Research in 1997, he served as Director of Laboratory Operations and Senior Staff Scientist at Hazleton Laboratories America  (now Covance) in Vienna, Virginia, and Director of Toxicology at Southern Research Institute in Birmingham, Alabama. He has conducted and reported more than  1,000 toxicology studies during his career in the preclinical research industry. Dr. Serota is a Diplomate of the American Board of Toxicology and is a 25-year full member of The Society of Toxicology, having served on both the Public Communications and the Placement Committees of that organization. He has given numerous presentations at a variety of scientific and technical meetings, and he is actively involved in presenting talks to students at local secondary education institutions on the role of and need for animal testing. Please join us in congratulating Dr. Serota in his new leadership role with ACT!

MPI Research, with global headquarters in Mattawan, Michigan, provides safety evaluation, discovery, bioanalytical, and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective
products to the world. Learn more about how we can exceed your expectations at www.mpiresearch.com.

Read 1447 times Last modified on Monday, 30 January 2012 10:28

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

Want more? Visit...

Videos

  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses the launch of ICON's new acquisition of Firecrest at Partnerships in Clinical Trials 2012. Facing the continuing challenge of not only monitoring and…
    Read more...
  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses their exciting new partnership with Roche at Partnerships In Clinical Trials 2012. Medical imaging has always been a strong department within ICON. ICON…
    Read more...
  • ERT- Partnerships 12
    ERT- Partnerships 12 John Blakely, Executive Vice President and Chief Commercial Officer for ERT discusses the new trend in clinical research at Partnerships in Clinical Trials 2012 - the melding of objective and…
    Read more...
  • Chiltern- Partnerships 12
    Chiltern- Partnerships 12 Marcelo Piccirillo, Senior Clinical Research Physician for Chiltern, discusses new trends in gastrointestinal clinical development at Partnerships in Clinical Trials 2012. Current hot spots for clinical development in the field…
    Read more...
  • Blinded Diagnostics - Partnerships 12
    Blinded Diagnostics - Partnerships 12 Paul Savuto, President and CFO, and Steven Karrupan, CEO, from Blinded Diagnostics discuss Point of Care Technology at Partnerships in Clinical Trials 2012. Point of care (or decentralized testing) offers…
    Read more...
  • American Airlines - IQPC 2011
    American Airlines - IQPC 2011 American Airlines has globally launched a passive solutions that gives a new alternative to pharmaceutical manufacturers.
    Read more...

Podcasts